Potential Agitation Treatment, AXS-05, Shows Efficacy and Safety in Phase 2/3 Trial

Potential Agitation Treatment, AXS-05, Shows Efficacy and Safety in Phase 2/3 Trial
Axsome Therapeutics' investigational oral therapy AXS-05 significantly and rapidly lessened agitation in patients with Alzheimer’s disease, top-line results from a Phase 2/3 trial show. The therapy was also found to be generally well-tolerated and safe, without affecting cognition. “I am very pleased to see the promising results of the ADVANCE-1 trial, providing clear evidence of reduced agitation in Alzheimer’s disease by this investigational medicine,” Jeffrey Cummings, MD, ScD, director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health, and Chambers professor of brain science at the University of Nevada Las Vegas, said in a press release. AXS-05 aims to treat agitation — an umbrella term that refers to feelin
Subscribe or to access all post and page content.